Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalamide SCHEMBL17907469 | 0.93 | ALDH1A1 (0.62) | PARP10ALDH1A1LMNACES2CES1 | |
| SCHEMBL76475 | 0.93 | ALDH1A1 (0.62) | PARP10ALDH1A1LMNACES2CES1 | |
| Hydrazine SCHEMBL28484381 | 0.90 | ALDH1A1 (0.59) | PARP10ALDH1A1LMNACES2CES1 | |
| Hydrochloric Acid SCHEMBL4376615 | 0.90 | ALDH1A1 (0.59) | PARP10ALDH1A1LMNACES2CES1 | |
| SCHEMBL30775329 | 0.90 | ALDH1A1 (0.59) | PARP10ALDH1A1LMNACES2CES1 | |
| Hydrochloric Acid SCHEMBL1776305 | 0.90 | ALDH1A1 (0.59) | PARP10ALDH1A1LMNACES2CES1 | |
| SCHEMBL10416433 | 0.90 | ALDH1A1 (0.59) | PARP10ALDH1A1LMNACES2CES1 | |
| Terephthalamide SCHEMBL27683041 | 0.90 | PARP10 (0.58) | PARP10ALDH1A1LMNAPARP1PARP4 | |
| Hydrochloric Acid SCHEMBL4879563 | 0.88 | ALDH1A1 (0.56) | PARP10ALDH1A1LMNACES2CES1 | |
| Benzene SCHEMBL28164652 | 0.88 | PARP1 (0.64) | PARP10ALDH1A1LMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0765357-B9 | ANTIVIRAL DENDRIMERS | STARPHARMA PTY LTD (AU) | 2006-08-16 | — | — | EP | claimed |
| EP-0765357-B8 | ANTIVIRAL DENDRIMERS | STARPHARMA PTY LTD (AU) | 2006-03-08 | — | — | EP | claimed |
| EP-0765357-B1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 2005-12-14 | — | — | EP | claimed |
| US-6190650-B1 | FOR PROPHYLAXIS AND THERAPY OF VIRAL DISEASES IN HUMANS AND ANIMALS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 2001-02-20 | — | — | US | claimed |
| EP-0765357-A4 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 1997-07-30 | — | — | EP | claimed |
| EP-0765357-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1997-04-02 | — | — | EP | claimed |
| WO-1995034595-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1995-12-21 | — | — | WO | claimed |
| US-9994444-B2 | Bridged polycyclic compound based compositions for the inhibition and amelioration of disease | ALLACCEM, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2125026-B1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM INC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8222239-B2 | quaternary ammonium compounds, conjugated to polymers, used as microbiocides | ALLACCEM, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2125026-A2 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | Allaccem, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. | 2008-11-06 | — | — | US | disclosed |
| EP-0765357-B8 | ANTIVIRAL DENDRIMERS | STARPHARMA PTY LTD (AU) | 2006-03-08 | — | — | EP | disclosed |
| EP-0765357-B1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 2005-12-14 | — | — | EP | disclosed |
| CN-1161128-C | Angiogenic inhibitory compounds | О | 2004-08-11 | — | — | CN | disclosed |
| US-6190650-B1 | FOR PROPHYLAXIS AND THERAPY OF VIRAL DISEASES IN HUMANS AND ANIMALS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 2001-02-20 | — | — | US | disclosed |
| EP-0765357-A4 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 1997-07-30 | — | — | EP | disclosed |
| EP-0765357-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034595-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | PARP10 960/4885ALDH1A1 1058/4885LMNA 312/4885 |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | PARP10 960/4885ALDH1A1 1058/4885LMNA 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.